MERCK FOSAMAX SALES REACH $58 MIL. IN U.S. DURING THIRD QUARTER; COZAAR, CRIXIVAN NEAR $50 MIL.; PFIZER ZITHROMAX SALES MORE THAN DOUBLE TO $75 MIL. IN U.S.
Executive Summary
Merck's Fosamax is tracking for over $200 mil. in sales in the U.S. during its first full year on the market. Fosamax sales reached $58 mil. in the U.S. for the third quarter, Merck reported Oct. 16. The osteoporosis agent was launched in the U.S. in October 1995, and has generated $141 mil. in sales so far in 1996. Worldwide sales are $79 mil. for the quarter and $189 mil. for the year to date, the company said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth